The Arthur Temple Sr. Regional Cancer Center

• Intensity Modulated Radioactive Treatment (IMRT)
   

• Two Siemens Oncor Multi-leaf Collimator Linear Accelerators which precisely treat cancer utilizing finely focused radiation beams
   

• The first permanent PET/CT scanner in the area for detecting abnormalities in the body
   

• Fusing of PET/CT and MRI images for treatment planning
   

• A treatment simulator, used to precisely define a patient’s field of treatment
   

• Treatment planning capabilities using the most advanced computer systems, including 3-D, IMRT, and the Anatom-E System
   

• An extensive brachytherapy program using radiation sources internally to treat cancer
   

• CT-Based Simulation
   

• Access to on-going clinical trials and new treatment options

The Arthur Temple Sr. Regional Cancer Center prides itself on treating the whole patient, not just the disease, by educating the patient on radiation therapy, nutrition, and the psycho-social aspects of having cancer.

The Arthur Temple Sr. Regional Cancer Center—rising above the rest in cancer care. Learn more about our services by speaking with a member of our cancer care team at 936-639-7468.

Ten Minutes That Could Save Your Life

Memorial Medical Center—Lufkin to Offer Free Screenings

 for Oral Cancer April 16

Just because you can’t feel it, doesn’t mean it isn’t there.  Ask the more than 35,000 Americans who were diagnosed with cancers of the head and neck last year.  Unfortunately, many Americans do not recognize the symptoms of these life-threatening diseases, which include cancers of the oral cavity, larynx and pharynx, and by the time they are diagnosed, for some, it’s too late.  In an effort to create awareness of these diseases and early detection, Memorial Medical Center—Lufkin will offer free screenings Friday, April 16, from 8 am to 3 pm at the Arthur Temple Sr. Regional Cancer Center.

The signs and symptoms of oral cancer often go unnoticed.  However, there are a few visible signs associated with these cancers that require immediate attention, including:

·         Red or white patches in the mouth that last more than two weeks

·         Change in voice or hoarseness that lasts more than two weeks

·         Sore throat that does not subside

·         Pain or swelling in the mouth or neck that does not subside

·         Lump in the neck

·         Ear pain

·         Difficulty speaking or swallowing

·         Difficulty breathing
 

Read the press release.

Memorial Health System of East Texas
Creates Awareness about Melanoma

With summer upon us and more outdoor activity opportunities, Memorial Health System of East Texas reminds everyone about the importance of skin protection from sunburn and ultraviolet (UV) light exposure. Though melanoma is not the most common type of skin cancer – basal cell carcinoma and squamous cell carcinoma predominate, melanoma is the leading cause of skin cancer related death.

The American Cancer Society estimates that the United States will have almost 69,000 new cases of melanoma and over 8,600 deaths from melanoma in 2009. Read the press release.

Memorial’s Arthur Temple Sr. Regional Cancer Center
Ranked One of the Best

The Arthur Temple Sr. Regional Cancer Center at Memorial Health System of East Texas is being recognized by the National Commission on Cancer for clinical excellence. As a result, The Commission on Cancer (CoC) of the American College of Surgeons has granted a three year approval with commendation to the local cancer program. According to the CoC only 25% of the cancer centers in the nation are accredited and less than half of those accredited achieve commendation.

According to the CoC the Arthur Temple Sr. Regional Cancer Center demonstrates a Commendation level of compliance with one or more standards that represent the full scope of the cancer program. This means that the hospital’s cancer program provides patients with comprehensive care, including a range of state-of-the-art services and equipment, a multispecialty team approach to coordinate the best treatment options, information about ongoing clinical trials and new treatment options, and access to cancer-related information, education, and support. Read the press release.